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Recognition of immunoglobulin G (IgG) by surface receptors for the Fc domain of immunoglobulin G (Fc),
FcRs, can trigger both humoral and cellular immune responses. Two human cytomegalovirus (HCMV)-
encoded type I transmembrane receptors with Fc-binding properties (vFcRs), gp34 and gp68, have been
identified on the surface of HCMV-infected cells and are assumed to confer protection against IgG-mediated
immunity. Here we show that Fc recognition by both vFcRs occurs independently of N-linked glycosylation
of Fc, in contrast with the properties of host FcRs. To gain further insight into the interaction with Fc,
truncation mutants of the vFcR gp68 ectodomain were probed for Fc binding, resulting in localization of the
Fc binding site on gp68 to residues 71 to 289, a region including an immunoglobulin-like domain. Gel
filtration and biosensor binding experiments revealed that, unlike host FcRs but similar to the herpes simplex
virus type 1 (HSV-1) Fc receptor gE-gI, gp68 binds to the CH2-CH3 interdomain interface of the Fc dimer with
a nanomolar affinity and a 2:1 stoichiometry. Unlike gE-gI, which binds Fc at the slightly basic pH of the
extracellular milieu but not at the acidic pH of endosomes, the gp68/Fc complex is stable at pH values from
5.6 to pH 8.1. These data indicate that the mechanistic details of Fc binding by HCMV gp68 differ from those
of host FcRs and from that of HSV-1 gE-gI, suggesting distinct functional and recognition properties.
Both alpha- and betaherpesviruses encode proteins that rec-
ognize the Fc region of immunoglobulin G (IgG) molecules
(Fc) (7, 18, 33). The viral Fc receptor (vFcR) in alphaher-
pesviruses is a heterodimer of the two transmembrane proteins
gE and gI, which are found in the viral envelope and on the
surface of infected cells (5, 15, 24, 30, 54). Studies with herpes
simplex virus type 1 (HSV-1) have shown that simultaneous
binding of human anti-HSV IgG to both an HSV antigen with
its Fab arms and to gE-gI with its Fc region, a phenomenon
referred to as antibody bipolar bridging, protects the virus and
infected cells from IgG-mediated immune responses (14, 16,
36, 51). gE-gI-mediated endocytosis of anti-HSV IgG/HSV
antigen complexes followed by degradation of anti-HSV IgG
has also been proposed based on the finding that gE-gI binds
Fc at pH 7.4 but does not bind at pH 6.0 (47). Biochemical
and structural analyses of gE-gI binding to Fc revealed that
gE-gI interacts with the Fc CH2-CH3 interdomain junction
with a stoichiometry of two molecules of gE-gI per Fc (47,
48). This symmetric interaction with Fc, which is a twofold
symmetric homodimer in which each polypeptide chain con-
tains an N-terminal hinge followed by the CH2 and CH3 do-
mains, is analogous to that previously identified for protein A
(11), protein G (43), rheumatoid factor (9), and FcRn (32).
Each of these proteins recognizes the CH2-CH3 interdomain
interface, which contains a six-residue consensus Fc binding
site (12). In contrast, host Fc receptors (FcRs; FcRI,
FcRIIa, FcRIIb, and FcRIII) bind Fc with 1:1 stoichiom-
etry in an asymmetric manner, contacting residues in the CH2
domain and in the CH1-CH2 hinge, which connects the Fab to
Fc (39, 45).
Even though Fc binding activity has long been reported for
cells infected with the betaherpesvirus human cytomegalovirus
(HCMV), the effects of Fc binding are unknown (17, 19, 26,
41, 42, 53). HCMV vFcRs gp34 and gp68 were recently dem-
onstrated to be encoded by independent genes, TRL11/IRL11
(3, 29) and UL119-UL118 (3), respectively. Both vFcRs, gp34
and gp68, were shown to be cell surface proteins that bind to
Fc (3, 29). gp34 and gp68 share binding properties with gE-gI,
the HSV-1 vFcR, in that each is specific for human IgG but
not human IgA or IgM. The HCMV vFcRs, however, bind all
four human IgG subclasses (IgG1, IgG2, IgG3, and IgG4) (2,
3), whereas gE-gI does not bind IgG3 (22, 55). gp34 and gp68
differ in their specificities for IgG from various mammal spe-
cies, with gp68 being more restrictive than gp34 (3). Although
gp34, gp68, gE-gI, and fcr-1/m138, the mouse cytomegalovirus-
encoded FcR (50), exhibit Fc binding activity, they do not
share sequence homology. Thus, each vFcR likely binds the
Fc region of IgG by a different set of interactions.
To facilitate an understanding of how HCMV vFcRs rec-
ognize IgG, we expressed and purified the ectodomains of gp34
and gp68 and characterized the interaction between gp68 and
Fc. We show that both vFcRs recognize Fc in a manner
independent of N-linked glycosylation of the Fc CH2 domain.
The gp34 ectodomain was unsuitable for biochemical charac-
terization because of aggregation. However, we used the gp68
ectodomain to demonstrate that the Fc binding region is
contained within gp68 residues 71 to 289, a region that includes
a predicted immunoglobulin-like domain, and that gp68 inter-
* Corresponding author. Mailing address: Division of Biology, Cal-
ifornia Institute of Technology, Pasadena, CA 91125. Phone: (626)
395-8350. Fax: (626) 792-3683. E-mail: bjorkman@caltech.edu.
† Present address: Department of Microbiology and Immunology,
Stanford University, Palo Alto, CA 94305.
 Published ahead of print on 23 January 2008.
3490
 at CALIFO
RNIA INSTITUTE O
F TECHNO
LO
G
Y on M
arch 14, 2008 
jvi.asm.org
D
ow
nloaded from
 
acts with the Fc CH2-CH3 interdomain junction with a nano-
molar affinity and a stoichiometry of two molecules of gp68 per
Fc dimer.
MATERIALS AND METHODS
Cells. African green monkey CV-I (ATCC CCL-70) and human tk143
(ATCC CRL-8303) cells were grown in Dulbecco modified Eagle medium sup-
plemented with 10% fetal calf serum, penicillin, streptomycin, and 2 mM glu-
tamine.
Viruses and plasmids. HSV-1 was propagated and the virus titer was determined
on Vero cells grown in Dulbecco modified Eagle medium containing 10% fetal calf
serum, penicillin, streptomycin, and 2 mM glutamine. The recombinant vaccinia
virus (rVV) gp68 expressing the FLAG epitope-tagged gp68 has been described
previously (3). The coding sequences of TRL11 (gp34) and UL119-UL118 (gp68)
were amplified from plasmids p7.5kTRL11FLAG (3) and p7.5kUL119-118FLAG
(3), respectively, using primer pairs 5-GTCTAGGGATCCATGCAGACCTACA
GCACCCC-3 and 5-GCTTAAGAATTCCTACTGTAAATCCCCGTCCACC
G-3 and 5-GACTTAGATCTACATGTGTTCCGTACTGGCG-3 and 5-GGAA
GAATTCTACCACTGCTTGAAGTAGGGCACCG-3, respectively. The PCR
fragments were cloned into the vaccinia virus recombination vector p7.5k131a via
BamHI and EcoRI and BglII and EcoRI, respectively (recognition sites are under-
lined). C-terminal truncation mutants of gp68 were generated using the forward
primer 5-GACTTAGATCTACATGTGTTCCGTACTGGCG-3 and the re-
verse primers 5-GAAACTAGTGTCCTCGAACAGCGGGTCGCTC-3 [gp68
(26–292), encoding residues 26 to 292], 5-GAAACTAGTCCGTTGTCCGTTAT
ACGTCACG-3 [gp68 (26–251), encoding residues 26 to 251] and 5-GAAACTA
GTCACGCGGACCCGCATCGTG-3 [gp68 (26–206), encoding residues 26 to
206] (where residue 1 is the N-terminal Met of the immature protein and residues
1 to 25 are predicted to define the signal peptide). The PCR fragments were cloned
using BglII and SpeI (recognition sites are underlined) into the vaccinia virus re-
combination vector p7.5k131a-FLAG containing the FLAG coding sequence after a
SpeI site, resulting in vaccinia virus recombination vectors that encode C-terminally
FLAG-tagged truncation mutants of gp68 [gp68 (26–292), gp68 (26–251), and gp68
(26–206)]. For the gp68 (71–292) mutant, the 5-end region (nucleotides [nt] 1 to 84)
and the 3-end region (nt 213 to 876) were separately amplified using primer pairs
5-GACTTAGATCTACATGTGTTCCGTACTGGCG-3, 5-CGCGCTAGCGC
TTGTGGTGCTACTTTTC-3 and 5-GCGGCTAGCACGACGCAGAAAGAG
GGG-3, 5-GAAACTAGTGTCCTCGAACAGCGGGTCGCTC-3, respectively,
digested with NheI (recognition sites are underlined), and ligated. After PCR am-
plification using primer pair 5-GACTTAGATCTACATGTGTTCCGTACTGGC
G-3 and 5-CGCGAATTCTACATGTAGGTCACGTACAAAAG-3, the product
was digested by BglII and EcoRI (recognition sites are underlined) and ligated into
the BamHI and EcoRI sites of the V5/six-His-tag coding vector pGene/V5-His B
(Invitrogen, Karlsruhe, Germany). The resulting DNA encoding gp68 (71–292) with
a C-terminal V5/six-His tag was subcloned into the vaccinia virus recombination
vector p7.5k131a. The human high-affinity Fc receptor Ia (CD64; GenBank acces-
sion no. NP000557) was cloned from CD64 cDNA (1) into p7.5k131a, using primer
pair 5-CACAGGATCCATGTGGTTCTTGACAACTC-3 and 5-AGCTGAGCT
CCTACGTGGCCCCCTGGGGCTC-3 and restriction enzymes BamHI and SacI
(recognition sites are underlined). The human medium-affinity Fc receptor IIa
(CD32; GenBank accession no. NP067674) was cloned from CD32 cDNA into
p7.5k131a using primer pair 5-GAGAAGATCTATGTCTCAGAATGTATGTCC
C-3 and 5-AGCTGAGCTCTTAGTTATTACTGTTGACATG-3 and restriction
enzymes BglII and SacI (recognition sites are underlined).
Generation of rVVs. The construction of rVVs has been described elsewhere
(49). Briefly, the gene of interest inserted in the vaccinia virus recombination
vector p7.5k131a was transferred into the thymidine kinase open reading frame
of the virus genome (strain Copenhagen). rVVs were selected with bromode-
oxyuridine (100 g/ml) using tk143 cells.
Immunoprecipitation and immunoblotting. For characterization of the bind-
ing of gp68 truncation mutants to Fc, CV-I cells were infected with rVVs (5
PFU/cell) for 14 h, washed twice with ice-cold phosphate-buffered saline (pH
7.2), and lysed on ice in 1% NP-40-lysis buffer (140 mM NaCl, 20 mM Tris pH
7.6, 5 mM MgCl2, 1 mM phenylmethylsulfonyl fluoride, 50 M leupeptin, and 1
M pepstatin A). One microgram of human Fc fragment (Rockland Immuno-
chemicals, Gilbertsville, PA), 1 g mouse anti-V5 antibody (Invitrogen,
Karlsruhe, Germany), or 4 g goat anti-FLAG antibody-coupled agarose (Bethyl
Laboratories, Montgomery, TX) was added to the postnuclear supernatant for
1 h at 4°C. Fc and potentially associated proteins were precipitated using
protein A- or protein G-Sepharose (GE Healthcare, Munich, Germany) over-
night at 4°C. Pellets were washed three times with a low-salt buffer (150 mM
NaCl, 2 mM EDTA, 10 mM Tris [pH 7.6], 0.2% NP-40), two times with a
high-salt buffer (500 mM NaCl, 2 mM EDTA, 10 mM Tris [pH 7.6], 0.2%
NP-40), and once with 10 mM Tris (pH 8.0). An aliquot of the precipitate was
digested with endoglycosidase H (Endo H; Roche, Mannheim, Germany) for
14 h using 5 mU according to the manufacturer’s instructions. Proteins were
separated by use of 4 to 12% gradient sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE), transferred to a nitrocellulose membrane, and
probed with mouse anti-FLAG M2 antibody (Sigma-Aldrich, Munich, Germany)
or mouse anti-V5 antibody. For detection, a peroxidase-coupled goat anti-mouse
antibody (Dianova, Hamburg, Germany) was visualized using the ECL Plus
chemiluminescence system (GE Healthcare).
Immunoprecipitation analyses of metabolically labeled proteins were per-
formed as described previously (3). In brief, proteins were labeled for 1 h with
35S-labeled Redivue Pro-Mix (GE Healthcare), followed by lysis and washing
procedures as described above. Untreated human Fc (1 g; Rockland), enzy-
matically deglycosylated human Fc, or mouse anti-human CD64 (2 g; Ancell
Corp., Bayport, MN) were incubated for 1 h at 4°C before protein A- or protein
G-Sepharose was added for an additional hour at 4°C. Before wild-type Fc
(wtFc) and nonbinding Fc (nbFc) were used for protein precipitations, Fc
proteins were covalently coupled to cyanogen bromide-activated (CNBr) Sepha-
rose (GE Healthcare) according to manufacturer’s instructions. Postnuclear cell
lysates were precleared first with mock coupled CNBr Sepharose before the
Fc-coupled Sepharose was added for 1 h at 4°C. The immune complexes were
dissociated in sample buffer and separated by 10% SDS-PAGE or 10 to 13%
gradient SDS-PAGE. Dried gels were exposed to Kodak BioMaxMR films at
70°C for 1 to 5 days.
Deglycosylation of human Fc. Twenty micrograms of human Fc (Rockland)
was deglycosylated overnight with either 0.025 U Endo H (Roche) or peptide
N-glycosidase F (Roche) according to the manufacturer’s instructions. Controls
were treated the same but without any enzyme. After dialysis against PBS (pH
7.2), precipitation of Fc was performed as described above. Deglycosylation of
Fc was verified by a shift in migration on silver-stained SDS-PAGE gels (data
not shown).
Expression and purification of soluble HCMV gp68 and HCMV gp34 proteins.
The gp68 ectodomain [gp68 (26–289)] and an N-terminally truncated form of the
gp68 ectodomain lacking the first 42 amino acids of the predicted mature protein
containing 25 potential O-GalNAc-glycosylation sites [gp68 (68–289)] were ex-
pressed in baculovirus-infected insect cells. DNA encoding gp68 (26–289) (res-
idues 26 to 289) with a C-terminal Factor Xa-cleavable six-His tag was PCR
amplified and subcloned between the BamHI and EcoRI sites of pAcGP67A
(Pharmingen) in frame with the gp67 signal peptide. DNA encoding gp68 (68–
289) (residues 68 to 289) was PCR amplified and subcloned in frame with the
HSV-1 gI signal peptide and C-terminal factor Xa-cleavable six-His tag of an
HSV-1 gI expression construct with a pAcUW51 (Pharmingen) backbone (47)
using BstXI and AvrII. Recombinant baculovirus stocks were generated by
cotransfection of the expression plasmids with linear wild-type baculovirus DNA
in Hi5 insect cells (Invitrogen). Supernatants of baculovirus-infected Hi5 cells
containing gp68 (26–289) or gp68 (68–289) were buffer exchanged into Ni-
binding buffer (40 mM Tris pH 8, 300 mM NaCl, 10 mM imidazole) and passed
over a Ni-nitrilotriacetic acid agarose column (Qiagen). gp68 (26–289) and gp68
(68–289) were eluted in the same buffer containing 250 mM imidazole and
further purified by size-exclusion chromatography on a Superdex 75 HiLoad
16/60 column (GE Healthcare) that was equilibrated in 20 mM HEPES (pH
7.8)-150 mM NaCl. Analysis of the peak fractions on a 12% SDS-PAGE gel
showed bands migrating with an apparent molecular mass of 55 and 35 kDa for
gp68 (26–289) and gp68 (68–289), respectively (see Fig. 4A). The gp34 ectodo-
main [gp34 (24–182)] was overexpressed in CHO cells. DNA encoding gp34
(24–182) (residues 24 to 182, where residue 1 is the N-terminal Met of the
immature protein and residues 1 to 23 are predicted to define the signal peptide)
was PCR amplified with a C-terminal factor Xa-cleavable six-His tag and sub-
cloned in frame with the rat IgG2a signal sequence into pBJ5-GS (31), a mam-
malian expression vector that carries the glutamine synthetase gene as a means
of selection and amplification in the presence of the drug methionine sulfoximine
(6). Stable cell lines expressing gp34 (24–182) were generated by Lipofectamine
2000 (Invitrogen) transfection of the expression plasmid in CHO cells. gp34
(24–182) was purified from CHO cell supernatants on a human IgG-Sepharose
column (GE Healthcare) by washing them with 40 mM Tris (pH 8)-300 mM
NaCl and eluting them with 50 mM diethylamine (pH 11.5) that was immediately
neutralized with 1 M Tris (pH 7), followed by a HiTrap chelating high-perfor-
mance column (GE Healthcare) eluted with 40 mM Tris (pH 8)-300 mM NaCl-
250 mM imidazole. The aggregation state of gp34 (24–182) was analyzed on a
Superdex 75 HR 10/30 column (GE Healthcare).
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Gel filtration binding assay. wtFc, heterodimeric Fc (hdFc), and nbFc, ex-
pressed in CHO cells and purified as described previously (47), were each mixed
with gp68 (68–289) in 2:1 [104 M gp68 (68–289), 52 M Fc] and/or 1:1 [52 M
gp68 (68–289), 52 M Fc] molar ratios in 50-l total volumes and injected onto
a Superdex 200 10/30 column (GE Healthcare) in 20 mM HEPES (pH 7.8)-150
mM NaCl. wtFc, hdFc, and nbFc were each examined alone at a concentration
of 52 M; gp68 (68–289) was examined alone at a concentration of 52 M. A 1:1
molar ratio of gp68 (68–289) and hdFc was also run under acidic conditions in 50
mM sodium citrate (pH 5.6)-150 mM NaCl-1 mM EDTA.
Biosensor studies. Surface plasmon resonance studies were performed using a
BIAcore 2000 instrument. For the affinity analyses of gp68 binding to wtFc and
hdFc, purified recombinant wtFc, hdFc, and nbFc were each immobilized on a
research-grade CM5 biosensor chip (Biacore) using primary amine coupling as
described in the Biacore manual. gp68 (26–289) and gp68 (68–289) were each
injected over a chip where one flow cell was mock coupled with buffer only and
the other three flow cells were coupled with either wtFc, hdFc, or nbFc at low
coupling densities (100 to 200 resonance units ([RU]). Threefold dilutions of
gp68 (26–289) and gp68 (68–289) were made starting at 6,000 nM and ending at
8 nM and assayed in 50 mM HEPES (pH 7.8 or 8.1), 150 mM NaCl, 3 mM
EDTA, and 0.005% (vol/vol) P-20 surfactant at a flow rate of 50 l/min. The
signal returned to baseline after approximately 30 min, indicating complete
dissociation of the gp68/Fc complex and thus regeneration of the Fc-coupled
biosensor surface. Kinetic binding data were analyzed with both mono- and
bivalent ligand models using Clamp (35), resulting in equilibrium dissociation
constants (KDs) for either a single-binding event, KD, or the first and second
binding events, KD1 and KD2, as described previously (47). For the comparison of
gp68 binding to hdFc at pH 6.0 and pH 8.1, gp68 (68–289) was immobilized using
primary amine coupling, as described above, and threefold dilutions of hdFc
were injected at pH 8.1 (50 mM HEPES [pH 8.1], 150 mM NaCl, 3 mM EDTA,
0.005% [vol/vol] P-20 surfactant) or pH 6.0 (50 mM sodium phosphate [pH 6.0],
150 mM NaCl, 3 mM EDTA, 0.005% [vol/vol] P-20 surfactant) at a flow rate of
5 l/min. The KD was determined at each pH by fitting the equilibrium binding
response as a function of hdFc concentration to a single-site binding model.
RESULTS
Intact binding of the HCMV FcRs gp34 and gp68 to de-
glycosylated Fc. The Fc is a homodimer formed by two
N-linked glycopeptide chains, each of which contains two im-
munoglobulin constant domains, CH2 and CH3. The chains
form a covalent dimer through interchain disulfide bonds in
the N-terminal hinge region. In addition, the CH3 domains pair
through protein-protein interactions, and the CH2 domains
interact through N-linked oligosaccharide chains that are at-
tached to Asn297. It is well established that glycosylation of Fc
is essential for recognition and activation of host FcRs (21),
which recognize the CH1-CH2 hinge and CH2 domain of Fc
(45). As a consequence, removal of the N-glycan results in a
loss of FcR binding (44, 52). By contrast, carbohydrate de-
pletion of IgG does not prevent binding by the Staphylococcus
aureus Fc receptor protein A (37), which contacts the interface
between the CH2 and CH3 domains (11). To test whether the
interaction of the HCMV FcRs gp34 and gp68 with Fc is
sensitive to the presence of carbohydrate on Fc, we compared
the binding levels of the vFcRs to enzymatically deglyco-
sylated Fc and to glycosylated Fc. The HCMV FcRs and a
control protein, the host FcRI (CD64), which binds glyco-
sylated but not deglycosylated Fc (44), were expressed by
rVVs and precipitated from lysates following metabolic label-
ing of cells using both forms of Fc. A lysate of CV-I cells
infected with wild-type VV (wtVV) (Fig. 1, lanes 1 to 5),
precipitation of gp34, gp68, and CD64 with untreated Fc (Fig.
1, lanes 1, 6, 11, and 21), and immunoprecipitation of CD64
using a specific antibody (Fig. 1, lane 16) were used as controls
for binding. As expected, the binding capacity of deglyco-
sylated Fc to CD64 was strongly impaired (Fig. 1, lanes 17
and 18). In contrast, gp34 and gp68 exhibited strong and un-
altered binding activities to deglycosylated Fc in comparison
to glycosylated, mock-treated Fc (Fig. 1, lanes 7 to 10 and 12
to 15). These results exclude direct binding of HCMV gp34
and gp68 to the Asn297-linked glycan and indicate a conforma-
tional requirement for Fc recognition different from that of
host FcRs (27, 44). Moreover, gp34 and gp68 exhibit a glycan-
independent binding mode to Fc like the Staphylococcus au-
reus protein A, although neither HCMV protein interferes
with Fc binding to protein A (3).
Amino acids 71 to 292 of HCMV gp68 are required for Fc
binding. The HCMV UL119-UL118-encoded FcR gp68 is a
type I transmembrane protein with an N-terminal hydrophobic
FIG. 1. Consequences of Fc deglycosylation for HCMV FcRs (A) and CD64 (FcRI) (B) binding. CV-I cells were infected with rVV or
wtVV at a multiplicity of infection of 5 for 14 h. [35S]methionine-labeled cells were lysed in 1% NP-40 lysis buffer, and precipitation of proteins
was performed with either enzymatically deglycosylated Fc (F, peptide N-glycosidase F treated; H, Endo H treated), mock-treated Fc (cF or cH;
no enzyme added), untreated Fc (), or anti-CD64 antibody followed by protein A- or protein G-Sepharose. Precipitated proteins were separated
by SDS-10 to 13% PAGE. Partially glycosylated forms of gp34 and gp68 (3) are indicated by asterisks. , anti-.
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signal peptide (comprising the first 25 to 28 residues) and
carrying multiple predicted N- and O-linked glycans within the
mature ectodomain (Fig. 2A). An immunoglobulin-like do-
main in good agreement with the consensus sequence for vari-
able-like domains (40) is predicted for gp68 residues 91 to 190.
The putative immunoglobulin-like domain includes position-
ally conserved cysteines, Cys116 and Cys169 (3), and showed its
highest degree of sequence identity to the third domain of
FcRI (CD64) (20% amino acid identity and 31% amino acid
similarity). To test whether the region including the immuno-
globulin-like domain is involved in Fc recognition and to
define the minimal region of gp68 required for Fc binding,
soluble gp68 truncation mutants, each lacking the predicted
transmembrane and cytoplasmic regions of the protein, were
constructed. The following gp68 truncation mutants were ex-
pressed with a C-terminal FLAG epitope (Fig. 2A), which
allowed for verification of protein expression by immunopre-
cipitation with FLAG-specific antibodies: gp68 (26–292) (the
complete ectodomain), gp68 (26–251) (mutant lacking 41 C-
terminal residues of the ectodomain), and gp68 (21–206) (mu-
tant lacking 84 C-terminal residues of the ectodomain). A
further deletion mutant was constructed to remove residues at
the N terminus of the ectodomain predicted to contain 25
potential O-glycans. This mutant, referred to as gp68 (71–292),
was constructed by fusing the N-terminal signal sequence of
gp68 to residues 71 to 292 followed by C-terminal V5/six-His
FIG. 2. Schematic representation of gp68 truncation mutants and their Fc binding properties. (A) The immature full-length gp68 (gp68FL)
contains a predicted 25 residue N-terminal signal peptide (indicated by an open rectangle) followed by an 268-residue ectodomain (residues
26 to 293), 21-residue transmembrane region (residues 294 to 314), and 31-residue cytoplasmic tail (residues 315 to 345). All gp68 mutants are
secreted proteins that lack the transmembrane and cytosolic domains and contain a C-terminal FLAG or V5/six-His tag as indicated. The predicted
molecular mass of each deglycosylated and glycosylated HCMV gp68 mutant is indicated on the right. TM, transmembrane region; signal, signal
peptide; Ig-like domain, immunoglobulin-like domain. (B) The truncated forms of gp68 were expressed by rVVs and precipitated from cell lysates
either with human Fc and protein A-Sepharose or with goat anti-FLAG antibody coupled to agarose or with mouse anti-V5 antibodies and
protein G-Sepharose. Cell lysates from CV-I cells infected with wtVV or mock infected were used as controls. An aliquot of the precipitate was
deglycosylated by Endo H treatment prior to separation of the proteins by gradient SDS-PAGE. After transfer to a nitrocellulose membrane,
proteins were detected using an anti-FLAG M2 or anti-V5 antibody. Bands of Fc due to cross-reactivity of the secondary anti-FLAG M2 antibody
are indicated by asterisks. WB, Western blot analysis; IP, immunoprecipitation; , anti-.
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epitopes. All gp68-derived mutants were expressed by rVVs,
and proteins with Fc-binding properties were precipitated
from cell lysates with Fc or epitope tag-specific antibodies,
separated by SDS-PAGE, and detected by immunoblotting
using epitope-specific IgG (Fig. 2B). Lysates from cells in-
fected with wtVV or mock-infected cells were used as controls.
Epitope-specific antibodies immunoprecipitated mutant pro-
teins that exhibited the expected molecular masses (Fig. 2B,
left panel), as confirmed by deglycosylation using Endo H (Fig.
2B, right panel). Binding to Fc, however, was restricted to
gp68 (26–292), containing the complete gp68 ectodomain, and
gp68 (71–292), which lacked the N-terminal O-glycosylated
subdomain (Fig. 2B). Removal of residues 206 to 292 abro-
gated Fc binding, pointing to an indispensable contribution of
this region of the gp68 ectodomain, which is located C termi-
nally from the putative immunoglobulin-like domain, in the
Fc interaction.
Fc binding characteristics of gp68 differ from those of host
CD64 (FcRI) and CD32 (FcRII). The binding interface of
Fc bound to the host CD16 (FcRIII), defined by crystalli-
zation studies, is formed by domains 1 and 2 of CD16 and the
lower hinge region between the antibody Fab and Fc in con-
junction with a contact site on the CH2 domain of Fc, result-
ing in a 1:1 stoichiometry (45). A common set of residues on
Fc is involved in binding FcRs, although CD64 and CD32
also interact with Fc residues outside of the common set (44).
In contrast, biochemical and structural analyses of gE-gI bind-
ing to Fc revealed that gE-gI interacts with the Fc CH2-CH3
interdomain junction with a stoichiometry of two molecules of
gE-gI per Fc (47, 48). We previously demonstrated that
HSV-1 gE-gI does not bind to nbFc (a nonbinding mutant Fc
in which each Fc subunit contained six point mutations in the
CH2-CH3 domain interface) but retains normal binding to a
recombinant wtFc (47), consistent with crystallographic studies
of a 2:1 gE-gI/Fc complex (48). To analyze the mode of
interaction of the cytomegaloviral FcR gp68 to Fc, we com-
pared the binding levels of wtFc and nbFc to gp68, the host
FcRs CD32 and CD64, and HSV-1 gE-gI, respectively (Fig.
3). As expected, mutation of both chains in the CH2-CH3
interdomain hinge of the nbFc molecule caused a loss of bind-
ing to HSV-1 gE-gI but not to CD32 and CD64 (44, 47, 48).
The impaired interaction of CD32 to nbFc resulted from uti-
lization of additional residues outside of the common FcR
binding site in the hinge region/CH2 domain (44). Interest-
ingly, nbFc did not precipitate gp68, suggesting a binding mode
similar to that of the herpesviral FcR gE-gI.
Expression and purification of soluble HCMV gp68 and
HCMV gp34 proteins. Two soluble versions of gp68 were ex-
pressed in baculovirus-infected insect cells: the gp68 ectodo-
main [gp68 (26–289)] and an N-terminally truncated form of
the gp68 ectodomain [gp68 (68–289); similar to gp68 (71–292)
expressed using rVV] that lacks the first 42 amino acids of the
predicted mature protein containing 25 potential O-GalNAc-
glycosylation sites (25). Analysis of the purified proteins on a
12% SDS-PAGE gel showed bands migrating with an apparent
molecular mass of 55 and 35 kDa for gp68 (26–289) and gp68
(68–289), respectively (Fig. 4A).
The gp34 ectodomain [gp34 (24–182)] was expressed as a
secreted protein in CHO cells. Analysis of purified gp34 (24–
182) on a 12% SDS-PAGE gel under nonreducing conditions
revealed that 10% of the protein migrated with an apparent
molecular mass of 30 kDa and 90% migrated with an appar-
ent molecular mass of 60 kDa. By contrast, under reducing
conditions, most of the protein migrated with an apparent
molecular mass of 30 kDa (Fig. 4B). Thus, a disulfide-linked
gp34 homodimer [gp34 (24–182) contains 5 cysteines] may be
present in the nonreducing environment of the extracellular
milieu when the intact protein is present at the cell surface.
gp34 (24–182) eluted as a very broad peak on a size exclusion
column (data not shown), suggesting that our gp34 (24–182)
preparation contained multiple aggregated species and was not
suitable for further biochemical characterization.
The HCMV gp68 ectodomain binds the CH2-CH3 interdo-
main interface of human Fc. We previously used wtFc, nbFc,
FIG. 3. Fc binding characteristics of gp68 differ from those of host
CD64 (FcRI) and CD32 (FcRII). CV-I cells were infected with
rVVs expressing gp68 and the host Fc receptors CD32 and CD64 or
with HSV-1 strain F at a multiplicity of infection of 4 for 14 h before
metabolic labeling (as described in the legend to Fig. 1). Proteins were
precipitated using either wtFc or nbFc coupled to CNBr-activated
Sepharose. Dissociated immune complexes were separated by 10%
SDS-PAGE. IP, immunoprecipitation.
FIG. 4. SDS-PAGE analyses of purified recombinant gp68 and
gp34 ectodomains. (A) gp68 (26–289) and gp68 (68–289); (B) gp34
(24–182) under reducing (R) and nonreducing (NR) conditions.
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and a heterodimeric Fc containing one wtFc and one nbFc
chain (hdFc) to demonstrate that gE-gI binds Fc with a 2:1
stoichiometry (47). To address whether gp68 binds to the CH2-
CH3 interdomain interface region on Fc and to determine the
gp68/Fc binding stoichiometry, we designed a gel filtration
assay to compare the elution profiles of gp68 (68–289) mixed
with wtFc, hdFc, or nbFc, which were expressed in CHO cells
and purified as previously described (47). If the interaction
interface between gp68 (68–289) and Fc encompasses the Fc
CH2-CH3 interdomain interface, mixtures of gp68 (68–289)
with wtFc, hdFc, and nbFc will have different elution profiles
when run on a gel filtration column. Otherwise, if the residues
in the Fc CH2-CH3 interdomain interface do not significantly
contribute to the gp68 (68–289)/Fc interface, as in the Fc/
FcRIII complex (45), mixtures of gp68 (68–289) with each of
the Fc variants, which differ in residues located in the CH2-
CH3 interdomain interface region of one or both subunits, will
have similar elution profiles.
In the gel filtration assay, gp68 (68–289) eluted at 15.7 ml,
consistent with an 35-kDa monomeric protein, and wtFc,
nbFc, and hdFc eluted at 14.6, 14.4, and 14.2 ml, respectively,
consistent with dimeric Fc differing by one or two six-His tags
(Fig. 5A). When gp68 (68–289) was mixed with nbFc and
loaded onto the gel filtration column, the only peaks observed
were at 15.7 and 14.2 ml, identical to the elution volumes for
gp68 (68–289) and nbFc alone (Fig. 5A). The elution profile
for a mixture of gp68 (68–289) with hdFc, however, contained
a new peak at 13.0 ml (Fig. 5A). Likewise, elution profiles of
gp68 (68–289) with wtFc also contained additional species that
eluted at 12.5 and 12.3 ml depending on the molar ratio (Fig.
5A). The additional peaks observed for gp68 (68–289) in the
presence of either wtFc or hdFc in comparison to any of the
proteins alone demonstrate that gp68 (68–289) binds wtFc and
hdFc, consistent with the binding of gp68 (71–292) to Fc,
whereas the similarity between the elution profiles of either
gp68 (68–289) and nbFc alone and the mixture of gp68 (68–
289) and nbFc indicates that gp68 (68–289) does not bind
nbFc. Thus, gp68 (68–289) recognized wtFc by using at least
some of the six residues in the Fc CH2-CH3 interdomain in-
terface that were altered to create nbFc. Furthermore, binding
of gp68 (68–289) to hdFc suggests that the gp68 (68–289)
binding site on Fc is likely contained within a single Fc CH2-
CH3 interdomain interface instead of being composed of res-
idues located in the CH2-CH3 interdomain interface of both
subunits of the Fc dimer.
Two HCMV gp68 molecules bind to each wtFc. To deter-
mine the stoichiometry of the gp68 (68–289)/Fc interaction,
we analyzed the elution profiles of different molar ratios of
gp68 (68–289) and wtFc or hdFc, which contain two or one
potential binding sites, respectively. A 1:1 molar ratio of gp68
(68–289) to wtFc eluted as two peaks: one at 12.5 ml, corre-
sponding to a new species with a higher molecular mass than
either protein alone, and one at 14.5 ml, corresponding to
excess wtFc (50% of the initial wtFc) (Fig. 5A). When the
molar ratio was increased to 2:1, the major peak shifted to 12.3
ml, the excess wtFc peak disappeared, and there was a slight
excess of gp68 (68–289) (10% of the total sample) (Fig. 5A),
all of which indicate a stoichiometry of two gp68 (68–289)
molecules binding to one wtFc dimer. In addition, the elution
profile for a sample containing a 2:1 molar ratio of gp68 (68–
289) to hdFc contained a major peak at 13.0 ml, likely corre-
sponding to a 1:1 gp68 (68–289)/hdFc complex, and a minor
peak at 15.7 ml, corresponding to excess gp68 (68–289) [50%
of the initial gp68 (68–289)] (Fig. 5A). Thus, a comparison of
the binding characteristics of gp68 (68–289) to wtFc with those
to hdFc and nbFc, two CH2-CH3 interdomain interface vari-
ants, using a gel filtration chromatography assay demonstrated
that one molecule of gp68 (68–289) binds to the CH2-CH3
interdomain interface of each wtFc subunit, similar to the
binding of HSV-1 gE-gI to wtFc (47). In addition, the fact that
the gp68 (68–289)/wtFc complex migrated only slightly slower
than the 1:1 gp68 (68–289)/hdFc complex suggested that the
FIG. 5. Gel filtration assay revealing that one molecule of gp68
binds each CH2-CH3 interdomain interface of Fc. Elution profiles are
shown for mixtures of gp68 (68–289) with wtFc, hdFc, and nbFc, which
contain zero, one, and two CH2-CH3 mutant Fc chains (see text),
respectively, at pH 7.8 (A) and pH 5.6 (B). The elution volumes of
gp68, wtFc, hdFc, and nbFc, and 1:1 and 2:1 [gp68 (68–289)/Fc]
complexes are indicated with dotted lines. mAU, milli-absorbance
units.
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gp68 (68–289)/wtFc complex does not contain higher-order
multimers of 2:1 vFcR/Fc complexes.
Biosensor binding experiments support a bivalent binding
model with nanomolar affinities. Binding of the HCMV gp68
ectodomain variants to Fc were further characterized using a
surface plasmon resonance assay, in which wtFc (“ligand”) was
immobilized and gp68 (26–289) or gp68 (68–289) (“analyte”)
was injected. A comparison of the gp68 (26–289) and gp68
(68–289) binding curves with those predicted by mono- and
bivalent ligand models showed that the interactions between
gp68 (26–289) and wtFc and between gp68 (68–289) and wtFc
were best described by a bivalent ligand model (Fig. 6A),
consistent with the gel filtration studies that identified two
gp68 binding sites on wtFc. Using a bivalent ligand model, we
determined KDs for the first and second binding events (KD1
and KD2) in which gp68 interacts with Fc as follows: for gp68
FIG. 6. Surface plasmon resonance binding data for gp68 (26–289) and gp68 (68–289) binding to Fc. Sensorgrams for binding of injected gp68
(26–289) or gp68 (68–289) at various concentrations (6,000 nM, 2,000 nM, 667 nM, 222 nM, 74 nM, 25 nM, and 8 nM) at pH 7.8 over a wtFc surface
(200 RU of primary amine-coupled wtFc) (A) or a hdFc surface (100 RU of primary amine-coupled hdFc) (B) are shown in black. Fits for
a bivalent ligand binding model, which assumes two independent binding sites on Fc, and for a single-site binding model are shown as blue lines,
and affinities are indicated, with KD1 and KD2 corresponding to the first and second binding events, respectively, for the bivalent ligand model.
Residuals are shown below each fit. (C) Equilibrium binding responses for hdFc injected over gp68 (68–289) at pH 8.1 (triangles) or pH 6.0
(squares) are shown at various injection concentrations. Data are plotted as percent binding at equilibrium (normalized for maximal binding) for
each injection of hdFc and fit to a single-binding-site isotherm. The derived KDs are 60 nM at pH 6.0 and 300 nM at pH 8.1. Four independent
determinations of the KD at either pH 7.8 or 8.1 ranged from 85 nM to 300 nM; thus, the affinity of gp68 binding to Fc is similar, or even slightly
tighter, at pH 6.0 than at pH 8.1.
3496 SPRAGUE ET AL. J. VIROL.
 at CALIFO
RNIA INSTITUTE O
F TECHNO
LO
G
Y on M
arch 14, 2008 
jvi.asm.org
D
ow
nloaded from
 
(26–289) binding to immobilized wtFc, KD1 equals 470 nM and
KD2 equals 1,600 nM; for gp68 (68–289) binding to immobi-
lized wtFc, KD1 equals 140 nM and KD2 equals 240 nM (Fig.
6A). The finding that gp68 (68–289) binds wtFc with affinities
that are three- to sixfold tighter than those of the gp68 (26–
289)/wtFc interaction suggests that the N-terminal 42 residues
of the mature gp68 protein and their likely associated O-linked
glycans are not critical for recognition of Fc, consistent with
the Fc pulldown experiments that indicated similar binding
levels of Fc with gp68 (26–292) and with gp68 (71–292) (Fig.
2B). The KD values derived from an analysis of kinetic binding
data of gp68 to immobilized hdFc were similar to those for
gp68 binding to the highest-affinity site on wtFc [gp68 (26–
289), KD 	 300 nM; gp68 (68–289), KD 	 85 nM] (Fig. 6B),
confirming that the single binding site on hdFc mimics each of
the gp68 binding sites on wtFc. As expected, binding of the
gp68 ectodomains to 1 M nbFc was not detectable in this
assay (data not shown). Previous measurements of binding of
human Fc to acetone-fixed HCMV-infected human embry-
onic lung fibroblasts estimated a KD of 5 nM (2); however, this
value represents a macroscopic KD that includes avidity effects
due to cross-linking of IgG by gp68 proteins, gp34 proteins,
and complexes containing one of each vFcR.
The interaction between HCMV gp68 and Fc is stable at
acidic pH. The interaction between HSV-1 gE-gI and Fc is
sharply pH dependent, with a 10-fold decrease in affinity be-
tween pH 7.4 and pH 6.6 and unmeasurable binding at pH
values of 6.2 as determined by a Biacore assay (47). The
unusual pH sensitivity of the gE-gI/Fc interaction allowed for
easy regeneration of gE-gI-coupled biosensor chips after each
injection of Fc at acidic pH (pH 5.0) (47). However, when we
tried to set up a similar Biacore binding assay for gp68/Fc,
acidic pH did not disrupt the interaction between Fc and
gp68, and regeneration of the biosensor surface could be
achieved only with long dissociation times (
30 min). To verify
the lack of a sharp pH dependence for the gp68/Fc interac-
tion, we repeated the gel filtration binding assay at acidic pH
and measured the KD at acidic pH using a surface plasmon
resonance assay. In the gel filtration assay at pH 5.6, a 1:1
molar ratio of gp68 (68–289)/hdFc eluted from the column as
expected for a 1:1 complex (Fig. 5B), demonstrating the sta-
bility of the gp68/Fc complex in solution at pH 5.6. Further
assessment of the interaction at acidic pH by surface plasmon
resonance showed that the affinity for binding of gp68 (68–289)
to hdFc at pH 6 (KD	 60 nM) was similar to, and possibly even
tighter than, the affinities observed at pH 7.8 or pH 8.1 (KD 	
85 to 300 nM) (Fig. 6C). Thus, the gp68/Fc complex is stable
between pH 5.6 and 8.1, in contrast to the gE-gI/Fc complex.
DISCUSSION
Structural requirements for gp68 Fc binding. In this study
we have investigated the mode of HCMV vFcR binding to
Fc and found distinct differences in comparison with the
binding of host FcRs, on the one hand, and a prototypic
vFcR, HSV gE-gI, on the other hand. Our initial finding
revealed a fully maintained binding of gp34 and gp68 to de-
glycosylated Fc lacking the N-linked glycans that are attached
to Asn297. This finding was not expected based on the following
several facts: (i) the existing, albeit limited, sequence related-
ness of gp68 and gp34 with host FcRs (3) but not with her-
pesviral or microbial Fc binding proteins; (ii) the antagonistic
effect of gp34 and gp68 on the activation of distinct host FcRs
by immune complexes (E. Corrales-Aguilar and H. Hengel,
unpublished data); and (iii) the lack of gp34 and gp68 compe-
tition with Staphylococcus aureus protein A for Fc binding,
which contrasts to HSV gE-gI (8, 23). Removal of the N-linked
glycans results in conformational changes in the CH2 domain
and increased internal disorder of the Fc affecting the inter-
face between Fc and host FcRs (27, 56). Based on the fact
that gp34 and gp68 binding was insensitive to deglycosylation-
induced changes of the Fc, we hypothesized that a contact site
distinct from the CH2-proximal hinge region mediating binding
of the host FcRII and FcIII (45, 57) is more likely recog-
nized by the vFcRs. This assumption prompted us to take
advantage of recombinant Fc mutants of the CH2-CH3 inter-
domain interface, which had been used to map the site recog-
nized by HSV gE-gI (47). Our results demonstrated that Fc
binding of gp68, like the binding of gE-gI, is affected by mu-
tations at the CH2-CH3 domain interface, suggesting that gp68
contacts this region of Fc. Consistent with this suggestion,
gp68 formed a 2:1 complex with Fc. Although gp68 targets a
similar binding site on Fc, several findings support the notion
that gp68 adopts an Fc binding mode that differs from that of
HSV gE-gI, as follows: (i) stability of the gp68/Fc complex at
pH 6, (ii) a maintained strong binding to the IgG3 subclass (3),
(iii) a lack of competition with Staphylococcus aureus protein
A, and (iv) effects on IgG effector functions that differ from
those exerted by HSV gE (H. Reinhard, E. Corrales-Aguilar,
and H. Hengel, unpublished data).
Despite their selective binding to IgG with high affinities, the
herpesviral FcRs HSV gE-gI and mouse cytomegalovirus
(MCMV) m138/fcr-1 also exhibit IgG-independent functions.
HSV gE and gI play an important role in virus spread from cell
to cell (4, 13), and MCMV m138/fcr-1 attenuates NKG2D-
mediated NK cell responses, resulting in a severely attenuated
replication of gene deletion mutants in vivo (10, 28). By anal-
ogy, gp68 may also have additional functions that are unrelated
to Fc binding.
pH dependence of the gp68/Fc interaction. Although
HCMV gp68 and HSV-1 gE-gI share the same or an overlap-
ping binding site on Fc, the finding that the gp68/Fc inter-
action is stable at pH values between 5.6 and 8.1 but that gE-gI
binds only at neutral or basic pH raises the question whether
the downstream events after Fc binding differ for gp68 and
gE-gI. Binding of gE-gI to anti-HSV IgG/antigen complexes in
an antibody bipolar bridged complex has been shown to abro-
gate IgG-mediated immune responses (14, 16, 36, 51). gE-gI
may also contribute to immune evasion by transporting free
IgG and antibody bipolar bridged complexes into endosomes,
where the gE-gI/IgG complex would dissociate in the pH 6
environment of early endosomes, and IgG-antigen complexes
would be targeted for proteolytic degradation while gE-gI
would be recycled back to the cell surface (47). By contrast,
IgG is predicted to remain bound to gp68 in early endosomes.
Since both gp34 and gp68 are relatively short-lived proteins
that are rapidly endocytosed and eventually transported to
lysosomes and degraded (3), they could transport bound IgG
to lysosomes, where proteases could digest both gp68 and the
bound IgG.
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MCMV m138/fcr-1 glycoprotein is another surface-resident
vFcR that trafficks to endolysosomal compartments. In addi-
tion to its Fc binding capabilities, m138/fcr-1 down-modulates
CD80 (34), the NKG2D ligand H60, and murine UL16-binding
protein-like transcript (MULT-1) (28). The down-regulation
of MULT-1 is achieved by m138/fcr-1-mediated interference of
the recycling of surface MULT-1, leading to its subsequent
proteolytic degradation in a lysosomal compartment (28). In-
terestingly, both effects, i.e., MULT-1 removal from the cell
surface and Fc binding, are mediated by the same N-terminal
portion of the fcr-1 ectodomain (Ig1), which is one of three
putative immunoglobulin-like domains (28). Taken together, it
is tempting to speculate that herpesviral FcRs in general are
lysosomotropic proteins shuttling target proteins and IgG-im-
mune complexes from the cell surface to distinct endolyso-
somal compartments. Moreover, vFcRs may function to de-
liver their cargo to endosomal compartments where they can
be processed and loaded onto major histocompatibility com-
plex (MHC) molecules, usually class II MHC molecules but
also possibly class I MHC molecules involved in cross-presen-
tation provided that the MHC molecules escaped from down-
regulation by HCMV (20, 38). Thus, the observed pH differ-
ences of Fc binding and release from vFcRs may reflect
adaptation to specific pH values prevailing at certain sites
along the increasingly acidic milieu of the endolysosomal route
and therefore depend on vFcR destination.
In conclusion, this study provides evidence that HCMV gp68
has found a means to bind Fc that differs from those of both
host FcRs and vFcRs. In this context it should be mentioned
that the gp68 binding site at the CH2-CH3 interdomain junc-
tion is distant from the FcR binding sites involving the hinge
between the Fc and Fab domains and the upper portion of
the CH2 domain (45, 46). Since gp68, like HSV-1 gE-gI, is able
to antagonize host FcR-dependent responses (H. Reinhard,
E. Corrales-Aguilar, and H. Hengel, unpublished data), these
vFcRs must have evolved binding interactions that allow
them to simultaneously contact the CH2-CH3 interdomain in-
terface and to block the host FcR binding site. The structural
basis for these interactions remains an intriguing problem to be
solved.
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